Effect of xanthohumol on Th1/Th2 balance in a breast cancer mouse model

Oncology Reports

Volumn 39, Issue 1, 2018, Pages 280-288

  Zhang, Wenchao ^a   Pan, Yanlong ^a,b   Gou, Panhong ^a   Zhou, Cheng ^a   Qing Ma, Lian ^c   Liu, Qiming ^c   Du, Yuping ^a   Yang, Jinbo ^a   Wang, Qin ^a  

^a LANZHOU UNIVERSITY   (China)

^b GANSU UNIVERSITY OF CHINESE MEDICINE   (China)

^c Yumen Tuopu Science Development and Technology Co   (China)

Author keywords

Antitumor immunity; CTL responses; STAT4; Th1 Th2 balance; Xanthohumol

Indexed keywords

CA 15-3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; KI 67 ANTIGEN; PERFORIN; STAT4 PROTEIN; XANTHOHUMOL; ANTINEOPLASTIC AGENT; FLAVONOID; MUC1 PROTEIN, HUMAN; MUCIN 1; NOTCH RECEPTOR; PROPIOPHENONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER MODEL; CELL DIFFERENTIATION; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; POLARIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TH1 CELL; TH1 POLARIZATION; TH1 TH2 BALANCE; TH2 CELL; TUMOR VOLUME; UPREGULATION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG SCREENING; GENE EXPRESSION REGULATION; HUMAN; IMMUNOLOGY; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; FLAVONOIDS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KI-67 ANTIGEN; MICE; MICE, INBRED BALB C; MUCIN-1; PROPIOPHENONES; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; TH1 CELLS; TH2 CELLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85037073090     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2017.6094     Document Type: Article

References (52)

1. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 64: 252-271, 2014.
2. Wang GL and Lin ZB: The immunomodulatory effect of lentinan. Yao Xue Xue Bao 31: 86-90, 1996 (In Chinese).
3. Lei LS and Lin ZB: Effect of Ganoderma polysaccharides on T cell subpopulations and production of interleukin 2 in mixed lymphocyte response. Yao Xue Xue Bao 27: 331-335, 1992.
4. Zhang Q and Lin Z: Study on antitumor activity and mechanism of Ganoderma polysaccharides B. Zhongguo Zhong Xi Yi Jie He Za Zhi 19: 544-547, 1999 (In Chinese).
5. Jiang W, Zhao S, Xu L, Lu Y, Lu Z, Chen C, Ni J, Wan R and Yang L: The inhibitory effects of xanthohumol, a prenylated chalcone derived from hops, on cell growth and tumorigenesis in human pancreatic cancer. Biomed Pharmacother 73: 40-47, 2015.
6. Venè R, Benelli R, Minghelli S, Astigiano S, Tosetti F and Ferrari N: Xanthohumol impairs human prostate cancer cell growth and invasion and diminishes the incidence and progression of advanced tumors in TRAMP mice. Mol Med 18: 1292-1302, 2012.
7. Yoshimaru T, Komatsu M, Tashiro E, Imoto M, Osada H, Miyoshi Y, Honda J, Sasa M and Katagiri T: Xanthohumol suppresses oestrogen-signalling in breast cancer through the inhibition of BIG3-PHB2 interactions. Sci Rep 4: 7355, 2014.
8. Kunnimalaiyaan S, Sokolowski KM, Balamurugan M, Gamblin TC and Kunnimalaiyaan M: Xanthohumol inhibits Notch signaling and induces apoptosis in hepatocellular carcinoma. PLoS One 10: e0127464, 2015.
9. Kunnimalaiyaan S, Trevino J, Tsai S, Gamblin TC and Kunnimalaiyaan M: Xanthohumol-mediated suppression of Notch1 signaling is associated with antitumor activity in human pancreatic cancer cells. Mol Cancer Ther 14: 1395-1403, 2015.
10. Benelli R, Venè R, Ciarlo M, Carlone S, Barbieri O and Ferrari N: The AKT/NF-κB inhibitor xanthohumol is a potent anti-lymphocytic leukemia drug overcoming chemoresistance and cell infiltration. Biochem Pharmacol 83: 1634-1642, 2012.
11. Fowler DH: Rapamycin-resistant effector T-cell therapy. Immunol Rev 257: 210-225, 2014.
12. Xu W, Celeridad M, Sankar S, Webb DR and Bennett BL: CC-4047 promotes Th1 cell differentiation and reprograms polarized human Th2 cells by enhancing transcription factor T-bet. Clin Immunol 128: 392-399, 2008.
13. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG and Glimcher LH: A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100: 655-669, 2000.
14. Zhu J, Yamane H, Cote-Sierra J, Guo L and Paul WE: GATA-3 promotes Th2 responses through three different mechanisms: Induction of Th2 cytokine production, selective growth of Th2 cells and inhibition of Th1 cell-specific factors. Cell Res 16: 3-10, 2006.
15. Ouyang W, Löhning M, Gao Z, Assenmacher M, Ranganath S, Radbruch A and Murphy KM: Stat6-independent GATA-3 autoactivation directs IL-4-independent Th2 development and commitment. Immunity 12: 27-37, 2000.
16. Kurata H, Lee HJ, O'Garra A and Arai N: Ectopic expression of activated Stat6 induces the expression of Th2-specific cytokines and transcription factors in developing Th1 cells. Immunity 11: 677-688, 1999.
17. Oh S and Hwang ES: The role of protein modifications of T-bet in cytokine production and differentiation of T helper cells. J Immunol Res 2014: 589672, 2014.
18. Kidd P: Th1/Th2 balance: The hypothesis, its limitations, and implications for health and disease. Altern Med Rev 8: 223-246, 2003.
19. Liao D, Luo Y, Markowitz D, Xiang R and Reisfeld RA: Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS One 4: e7965, 2009.
20. Hong M, Jiang Z and Zhou YF: Effects of thermotherapy on Th1/Th2 cells in esophageal cancer patients treated with radiotherapy. Asian Pac J Cancer Prev 15: 2359-2362, 2014.
21. Yoshino S, Yoshimura K, Suzuki N, Iida M, Yoshida S, Maeda Y, Maeda K, Hazama S and Oka M: Immunoregulatory effects of PSK on the Th1/Th2 balance and regulatory T-cells in patients with colorectal cancer. Gan To Kagaku Ryoho 37: 2234-2236, 2010 (In Japanese).
22. Romagnani S, Maggi E and Del Prete G: An alternative view of the Th1/Th2 switch hypothesis in HIV infection. AIDS Res Hum Retroviruses 10: iii-ix, 1994.
23. Crane IJ and Forrester JV: Th1 and Th2 lymphocytes in autoimmune disease. Crit Rev Immunol 25: 75-102, 2005.
24. Matsuzaki J, Tsuji T, Imazeki I, Ikeda H and Nishimura T: Immunosteroid as a regulator for Th1/Th2 balance: Its possible role in autoimmune diseases. Autoimmunity 38: 369-375, 2005.
25. Zhihong Sun CZ, Feng Liu, et al: Inhibition of breast cancer cell survival by Xanthohumol via modulating Notch signaling pathway in vivo and in vitro. Oncology Letters: 15585229/12/2015.
26. Kast RE: Ribavirin in cancer immunotherapies: Controlling nitric oxide augments cytotoxic lymphocyte function. Neoplasia 5: 3-8, 2003.
27. Matar P, Rozados VR, Gervasoni SI and Scharovsky GO: Th2/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model. Cancer Immunol Immunother 50: 588-596, 2002.
28. Naito S, von Eschenbach AC, Giavazzi R and Fidler IJ: Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. Cancer Res 46: 4109-4115, 1986.
29. Guo HW, Yun CX, Hou GH, Du J, Huang X, Lu Y, Keller ET, Zhang J and Deng JG: Mangiferin attenuates TH1/TH2 cytokine imbalance in an ovalbumin-induced asthmatic mouse model. PLoS One 9: e100394, 2014.
30. Ubukata H, Motohashi G, Tabuchi T, Nagata H, Konishi S and Tabuchi T: Evaluations of interferon-γ/interleukin-4 ratio and neutrophil/lymphocyte ratio as prognostic indicators in gastric cancer patients. J Surg Oncol 102: 742-747, 2010.
31. Gao J, Zhang Q, Xu J, Guo L and Li X: Clinical significance of serum miR-21 in breast cancer compared with CA153 and CEA. Chin J Cancer Res 25: 743-748, 2013.
32. Tan QX, Qin QH, Yang WP, Mo QG and Wei CY: Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy. Int J Clin Exp Pathol 7 6862-6870, 2014.
33. Shurin MR, Lu L, Kalinski P, Stewart-Akers AM and Lotze MT: Th1/Th2 balance in cancer, transplantation and pregnancy. Springer Semin Immunopathol 21: 339-359, 1999.
34. Feili-Hariri M, Falkner DH and Morel PA: Polarization of naive T cells into Th1 or Th2 by distinct cytokine-driven murine dendritic cell populations: Implications for immunotherapy. J Leukoc Biol 78: 656-664, 2005.
35. Ma J, Liu H and Wang X: Effect of ginseng polysaccharides and dendritic cells on the balance of Th1/Th2 T helper cells in patients with non-small cell lung cancer. J Tradit Chin Med 34: 641-645, 2014.
36. Saxena R and Kaur J: Th1/Th2 cytokines and their genotypes as predictors of hepatitis B virus related hepatocellular carcinoma. World J Hepatol 7: 1572-1580, 2015.
37. Hong CC, Yao S, McCann SE, Dolnick RY, Wallace PK, Gong Z, Quan L, Lee KP, Evans SS, Repasky EA, et al: Pretreatment levels of circulating Th1 and Th2 cytokines, and their ratios, are associated with ER-negative and triple negative breast cancers. Breast Cancer Res Treat 139: 477-488, 2013.
38. Kiyofuji A, Yui K, Takahashi K and Osada K: Effects of xanthohumol-rich hop extract on the differentiation of preadipocytes. J Oleo Sci 63: 593-597, 2014.
39. Casaschi A, Maiyoh GK, Rubio BK, Li RW, Adeli K and Theriault AG: The chalcone xanthohumol inhibits triglyceride and apolipoprotein B secretion in HepG2 cells. J Nutr 134: 1340-1346, 2004.
40. Costa R, Rodrigues I, Guardão L, Lima JQ, Sousa E, Soares R and Negrão R: Modulation of VEGF signaling in a mouse model of diabetes by xanthohumol and 8-prenylnaringenin: Unveiling the angiogenic paradox and metabolism interplay. Mol Nutr Food Res 61: doi: 10.1002/mnfr.201600488, 2017.
41. Sasazawa Y, Kanagaki S, Tashiro E, Nogawa T, Muroi M, Kondoh Y, Osada H and Imoto M: Xanthohumol impairs autophagosome maturation through direct inhibition of valosin-containing protein. ACS Chem Biol 7: 892-900, 2012.
42. Lee IS, Lim J, Gal J, Kang JC, Kim HJ, Kang BY and Choi HJ: Anti-inflammatory activity of xanthohumol involves heme oxygenase-1 induction via NRF2-ARE signaling in microglial BV2 cells. Neurochem Int 58: 153-160, 2011.
43. Dorn C, Bataille F, Gaebele E, Heilmann J and Hellerbrand C: Xanthohumol feeding does not impair organ function and homoeostasis in mice. Food Chem Toxicol 48: 1890-1897, 2010.
44. Choi JM, Kim HJ, Lee KY, Choi HJ, Lee IS and Kang BY: Increased IL-2 production in T cells by xanthohumol through enhanced NF-AT and AP-1 activity. Int Immunopharmacol 9: 103-107, 2009.
45. Cho YC, You SK, Kim HJ, Cho CW, Lee IS and Kang BY: Xanthohumol inhibits IL-12 production and reduces chronic allergic contact dermatitis. Int Immunopharmacol 10: 556-561, 2010.
46. Liu Z, Lv D, Liu S, Gong J, Wang D, Xiong M, Chen X, Xiang R and Tan X: Alginic acid-coated chitosan nanoparticles loaded with legumain DNA vaccine: Effect against breast cancer in mice. PLoS One 8: e60190, 2013.
47. Mosmann TR and Sad S: The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 17: 138-146, 1996.
48. Sparano A, Lathers DM, Achille N, Petruzzelli GJ and Young MR: Modulation of Th1 and Th2 cytokine profiles and their association with advanced head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg 131: 573-576, 2004.
49. Pernis AB and Rothman PB: JAK-STAT signaling in asthma. J Clin Invest 109: 1279-1283, 2002.
50. Mowen KA and Glimcher LH: Signaling pathways in Th2 development. Immunol Rev 202: 203-222, 2004.
51. Chang HC, Han L, Goswami R, Nguyen ET, Pelloso D, Robertson MJ and Kaplan MH: Impaired development of human Th1 cells in patients with deficient expression of STAT4. Blood 113: 5887-5890, 2009.
52. Chen J, Wang Y, Mei Z, Zhang S, Yang J, Li X, Yao Y and Xie C: Radiation-induced lung fibrosis in a tumor-bearing mouse model is associated with enhanced type-2 immunity. J Radiat Res 57: 133-141, 2016.